HOTH News and Press, Hoth Therapeutics Inc. From 05/03/22

Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort PR Newswire The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severi...

Hoth Therapeutics (NASDAQ:HOTH) said it is adding a new asset to its pipeline, HT-TBI. The company said HT-TBI is being developed as a point-of-care therapy for treating secondary brain injury (such as brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury (TB...

Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury PR Newswire HT-TBI is a novel, point-of-care drug-device combination product under development for acute treatment of secondary brain injury resulting from ischemic stroke and ...

Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market PR Newswire NEW YORK , April 14, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today an...

Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM) +22%. Singularity Future Technology (SGLY) +2...

Gainers: Lixte Biotechnology LIXT +263%. BioCardia BCDA +29%. Biodesix BDSX +27%. Aeglea BioTherapeutics AGLE +16%. Actinium Pharmaceuticals ATNM +14%. Losers: Hoth Therapeutics HOTH -30%. Altamira Therapeutics CYTO -29%. Myovant Sciences (MYO...

Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference PR Newswire Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ ...

Hoth Therapeutics (NASDAQ:HOTH) is down 12.4% after hours after the firm has priced its underwritten public offering of 8,235,294 shares of common stock at $0.85/share for aggregate gross proceeds of ~$7.0M. Underwriters green shoe options is for another ~1.24M shares of common stoc...

Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market PR Newswire NEW YORK , April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today an...

The development-stage pharmaceutical company Hoth Therapeutics (NASDAQ:HOTH) followed up its impressive preclinical data for its investigational cancer therapy, HT-KIT with the start of an underwritten public offering of common stock on Monday. Following the announcement, the shares of the Ne...